Clinical trial · Interventional
Gustave Roussy Cancer Profiling
NCT04932525CI-TRIAL-00102739STINGrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of STING study is to perform high throughput molecular analysis (next generation sequencing +/- immunological profiling) to estimate the proportion of patients with cancer presenting at least one targetable genomic alteration.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor, Unspecified, Adult | Adult Solid Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- solid tumor or hematological malignancy
- interventionNames
- Procedure: Biopsy
Primary outcomes (2)
- measure
- Number of patients presenting at least one targetable genomic alteration
- timeFrame
- 2 months after the last enrollment
- description
- Number of patients presenting at least one targetable genomic alteration
- measure
- Proportion of patients presenting at least one targetable genomic alteration
- timeFrame
- 2 months after the last enrollment
- description
- Proportion of patients presenting at least one targetable genomic alteration
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years 2. Histology: solid malignant tumor or hematological malignancy. 3. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code) 4. Voluntary signed and dated written informed consent prior to any study specific procedure. Exclusion Criteria: 1. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol 2. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent 3. Pregnant or breast-feeding women 4. Minors (Age \< 18 years)
References
Publications (4)
- DERIVEDDawi L, Belkouchi Y, Lawrance L, Gautier O, Ammari S, Vasseur D, Wirth F, Hadchiti J, Morer S, David C, Bidault F, Balleyguier C, Kind M, Bayle A, Belcaid L, Aldea M, Nicotra C, Geraud A, Sakkal M, Blanc-Durand F, Moog S, Mosele MF, Tagliamento M, Bernard-Tessier A, Verret B, Smolenschi C, Auger N, Gazzah A, Micol JB, Caron O, Hollebecque A, Loriot Y, Besse B, Lacroix L, Rouleau E, Ponce S, Andre F, Soria JC, Barlesi F, Muller S, Cournede PH, Talbot H, Italiano A, Lassau N. Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases. Radiology. 2024 Nov;313(2):e232674. doi: 10.1148/radiol.232674. PMID 39589242
- DERIVEDRodriguez J, Baldini C, Bayle A, Pages A, Danlos FX, Vasseur D, Rouleau E, Lacroix L, Alonso de Castro B, Goldschmidt V, Seknazi L, Hollebecque A, Michot JM, Champiat S, Marabelle A, Ouali K, Marzac C, Ponce S, Micol JB, Chaput N, Massard C, Italiano A. Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial. JCO Precis Oncol. 2024 May;8:e2300631. doi: 10.1200/PO.23.00631. PMID 38815178
- DERIVEDHelal C, Pobel C, Bayle A, Vasseur D, Nicotra C, Blanc-Durand F, Naoun N, Bernard-Tessier A, Patrikidou A, Colomba E, Flippot R, Fuerea A, Auger N, Ngo Camus M, Besse B, Lacroix L, Rouleau E, Ponce S, Italiano A, Loriot Y. Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer. Eur J Cancer. 2023 Dec;195:113368. doi: 10.1016/j.ejca.2023.113368. Epub 2023 Oct 6. PMID 37897866
- DERIVEDAldea M, Tagliamento M, Bayle A, Vasseur D, Verge V, Marinello A, Danlos FX, Blanc-Durand F, Bernard E, Cerbone L, Mosele MF, Renneville A, Hadoux J, Loriot Y, Sakkal M, Vozy A, Sarkozy C, Smolenschi C, Nicotra C, Martin-Romano P, Boccon-Gibod C, Habza W, Lazarovici J, Ponce S, Hollebecque A, Marzac C, Lacroix L, Barlesi F, Andre F, Besse B, Rouleau E, Italiano A, Micol JB. Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors. JCO Precis Oncol. 2023 Mar;7:e2200583. doi: 10.1200/PO.22.00583. PMID 36862966